BIOSPACE article, july 2019

WUGEN attacks gaps in car-t therapy

ST. LOUIS, APR. 30, 2019

Wugen Adds to Leadership Team as Company Continues to Lay Groundwork for Future Expansion

ST. LOUIS, mar. 26, 2019

WUGEN Expands Leadership Team with Appointment of a Vice President of Research and Development and a Vice President of Product Development

ST. LOUIS, feb. 20, 2019

WUGEN Presents New Data for Key CAR-T Platform at the 2019 Transplantation & Cellular Therapy Meetings of ASBMT and CIBMTR

Presentations feature new preclinical data on WUGEN’s core fratricide-resistant CAR-T therapy platform targeting T-cell malignancies.

ST. LOUIS, DEC. 3, 2018

WUGEN Presents Updated Preclinical Data on Novel Allogeneic CAR-T Platform at ASH Annual Meeting

Platform demonstrates curative treatment of T-cell cancers using fratricide-resistant UCART in preclinical model.

ST. LOUIS, Nov. 13, 2018

WUGEN Announces Exclusive License Agreement for CAR-T Therapy Technologies from Washington University in St. Louis

ST. LOUIS, Nov. 1, 2018

WUGEN Announces Presentations at American Society of Hematology Annual Meeting

Company presents first clinically viable therapy to address a cancer with no effective targeted treatment